Also see: BofA, Blackrock: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES

Albermarle ( ALB) estimates, target were raised at Goldman Sachs. Shares are now seen reaching $74, and estimates were also raised, following the company's upbeat investor meeting, Goldman said. Buy rating.

Avon Products ( AVP) numbers were raised at Goldman Sachs through 2013. Company is realizing higher margins, Goldman said. Sell rating and new $29 price target.

Big 5 Sporting Goods ( BGFV) price target was cut at Credit Suisse to $10 from $16. Weaker first quarter due to expenses, and near-term outlook is weak, Credit Suisse said. Maintain Neutral rating.

CBS ( CBS) estimates, target were raised at UBS. Shares of CBS now seen reaching $30. Estimates were also increased, given better advertising momentum, UBS said. Buy rating.

Clorox ( CLX) estimates, target were lowered at Goldman Sachs. Shares of CLX now seen reaching $64, and estimates were also cut, given higher commodity costs, Goldman said. Neutral rating.

Corinthian Colleges ( COCO) price target was cut at Credit Suisse by a dollar to $4. Revenue and margins are likely to deteriorate from here, Credit Suisse said. Maintain Neutral rating.

Cisco Systems ( CSCO) estimates were reduced at UBS through 2012. Half of the company is not growing, UBS said. Neutral rating and $19 price target.

Dole Food ( DOLE) numbers were boosted at Goldman Sachs. Shares now seen reaching $14. Estimates also were raised, as profitability is improving in the fresh fruit business, Goldman said. Neutral rating.

Emerson Electric ( EMR) numbers cut at Goldman Sachs. Shares now seen reaching $67. Estimates also lowered, as the company is seeing lower network power demand. Buy rating.

Fidelity National Information Services ( FIS) price target raised at Citigroup to $40.50 from $37. Recent investments are performing better than expected, Citigroup said. Maintain Buy rating.

First Solar ( FSLR) price target was lowered at Credit Suisse to $115 from $137. Company did not increase its contracted backlog of system projects, and balance sheet metrics weakened, Credit Suisse said. Maintain Neutral rating.

First Solar estimates were cut at Morgan Stanley through 2012. Company lowered its guidance, and the outlook for Europe is cautious, Morgan Stanley said. Equal-weight rating.

Foster Wheeler ( FWLT) numbers were lowered at UBS. Shares now seen reaching $40, and estimates were also cut, given lower bookings, UBS said. Buy rating.

Hain Celestial Group ( HAIN) price target was raised at Citigroup to $42 from $34. Accelerating sales, EPS beat and solid outlook, Citigroup said. Maintain Buy rating .

Hain Celestial numbers were increased at UBS through 2012. Company is seeing better sales, and acquisitions are boosting growth, UBS said. Neutral rating and new $34 price target.

Impax Laboratories ( IPXL) numbers were raised at Goldman Sachs. Shares now seen reaching $29, and estimates were also boosted, to match the company's new guidance, Goldman said. Neutral rating.

Las Vegas Sands ( LVS) price target was lowered at Credit Suisse to $55 from $56. Meaningful upside potential as its properties continue to ramp, Credit Suisse said. Maintain Outperform rating.

Las Vegas Sands estimates were lowered through 2012 at Morgan Stanley. Singapore is not growing as quickly as expected, Morgan Stanley said. Overweight rating and $50 price target.

Mastercard ( MA) estimates, target raised at Goldman Sachs. Shares now seen reaching $315. Estimates also increased, as higher volumes are driving margin growth, according to Goldman. Buy rating.

McKesson ( MCK) price target was increased to $89 from $85 at Citigroup. Fourth-quarter EPS was inline, and revenue was better than expected, Citigroup said. Maintain Hold rating.

Marathon Oil ( MRO) numbers were boosted at UBS. Shares are now seen reaching $60. Estimates were also increased, given better downstream earnings, UBS said. Buy rating.

Genetics ( MYGN) numbers were increased at Goldman Sachs through 2013. Company boosted its guidance, though pricing remains uncertain, Goldman said. Sell rating and new $19 price target.

MetroPCS ( PCS) estimates, target increased at Goldman Sachs through 2013. Company is leveraged to smartphone momentum, Goldman said. Neutral rating and new $18 price target.

Pfizer ( PFE)estimates, target were boosted at Goldman Sachs. Shares now seen reaching $24. Estimates also raised, given expectations for increased buyback activity. Buy rating.

Perrigo ( PRGO) estimates, target upped at UBS. Estimates were boosted through 2012. Generic fundamentals remain strong, UBS said. Buy rating and new $100 price target.

Parexel ( PRXL) estimates, target were cut at Goldman Sachs. Shares now seen reaching $22. Estimates also lowered, to match the company's new guidance, Goldman said. Neutral rating.

Molson Coors ( TAP) numbers were reduced at Goldman Sachs. Shares now seen reaching $52. Estimates also cut, given lower volume and margins, according to Goldman Sachs. Neutral rating.

Tenneco ( TEN) price target was raised at Credit Suisse by a dollar to $59. Strong first quarter, operations drive earnings beat, Credit Suisse said. Maintain Outperform rating.

Tenneco estimates, target were increased at Goldman Sachs through 2013. Higher sales are driving margin expansion, Goldman said. Neutral rating and new $48 price target.

End of report.
This article was written by a staff member of TheStreet.

If you liked this article you might like

7 Investment Themes You Can't Afford to Miss for 2018

7 Investment Themes You Can't Afford to Miss for 2018

Marvell Technology, Albemarle, Dominion Energy: 'Mad Money' Lightning Round

Marvell Technology, Albemarle, Dominion Energy: 'Mad Money' Lightning Round

Consumers Are Ready to Spend: Cramer's 'Mad Money' Recap (Tuesday 1/9/18)

Consumers Are Ready to Spend: Cramer's 'Mad Money' Recap (Tuesday 1/9/18)

What it Takes to Power This Bull: Cramer's 'Mad Money' Recap (Thursday 11/30/17)

What it Takes to Power This Bull: Cramer's 'Mad Money' Recap (Thursday 11/30/17)

Seen the Yield Curve Lately? Neither Have Bond Traders: Market Recon

Seen the Yield Curve Lately? Neither Have Bond Traders: Market Recon